Movement Disorders
0885-3185
1531-8257
Mỹ
Cơ quản chủ quản: WILEY , John Wiley & Sons Inc.
Lĩnh vực:
Neurology (clinical)Neurology
Các bài báo tiêu biểu
Sự sửa đổi của Hiệp hội Rối loạn Vận động đối với Thang đánh giá Bệnh Parkinson Thống nhất (MDS‐UPDRS): Trình bày thang đo và kết quả kiểm tra clinimetric Tóm tắt Chúng tôi trình bày đánh giá metri lâm sàng của phiên bản do Hiệp hội Rối loạn Vận động (MDS) tài trợ, đó là bản sửa đổi của Thang Đánh Giá Bệnh Parkinson Thống nhất (MDS‐UPDRS). Nhóm công tác MDS‐UPDRS đã sửa đổi và mở rộng UPDRS dựa trên các khuyến nghị từ một bài phê bình đã công bố. MDS‐UPDRS có bốn phần, cụ thể là, I: Trải nghiệm Không vận động trong Sinh hoạt hàng ngày; II: Trải nghiệm Vận động trong Sinh hoạt hàng ngày; III: Khám nghiệm Vận động; IV: Biến chứng Vận động. Hai mươi câu hỏi được hoàn thành bởi bệnh nhân/người chăm sóc. Các hướng dẫn cụ thể theo từng mục và phần phụ lục của các thang đo bổ sung đi kèm được cung cấp. Các chuyên gia về rối loạn vận động và điều phối viên nghiên cứu thực hiện UPDRS (55 mục) và MDS‐UPDRS (65 mục) cho 877 bệnh nhân nói tiếng Anh (78% người da trắng không phải gốc Tây Ban Nha) bị bệnh Parkinson từ 39 địa điểm. Chúng tôi đã so sánh hai thang đo bằng cách sử dụng kỹ thuật tương quan và phân tích yếu tố. MDS‐UPDRS cho thấy tính nhất quán nội tại cao (hệ số Cronbach = 0.79–0.93 trên các phần) và tương quan với UPDRS gốc (ρ = 0.96). Tương quan giữa các phần của MDS‐UPDRS dao động từ 0.22 đến 0.66. Cấu trúc yếu tố đáng tin cậy cho mỗi phần đã được thu được (chỉ số vừa vặn so sánh > 0.90 cho mỗi phần), điều này ủng hộ việc sử dụng tổng số điểm cho mỗi phần thay vì tổng số điểm của tất cả các phần. Kết quả kết hợp của nghiên cứu này hỗ trợ tính hợp lý của MDS‐UPDRS trong việc đánh giá Parkinson. © 2008 Hiệp hội Rối loạn Vận động
Tập 23 Số 15 - Trang 2129-2170 - 2008
#Thang Đánh Giá Bệnh Parkinson Thống nhất #MDS‐UPDRS #rối loạn vận động #tính nhất quán nội tại #phân tích yếu tố
Systematic review of levodopa dose equivalency reporting in Parkinson's disease Abstract Interpretation of clinical trials comparing different drug regimens for Parkinson's disease (PD) is complicated by the different dose intensities used: higher doses of levodopa and, possibly, other drugs produce better symptomatic control but more late complications. To address this problem, conversion factors have been calculated for antiparkinsonian drugs that yield a total daily levodopa equivalent dose (LED). LED estimates vary, so we undertook a systematic review of studies reporting LEDs to provide standardized formulae. Electronic database and hand searching of references identified 56 primary reports of LED estimates. Data were extracted and the mean and modal LEDs calculated. This yielded a standardized LED for each drug, providing a useful tool to express dose intensity of different antiparkinsonian drug regimens on a single scale. Using these conversion formulae to report LEDs would improve the consistency of reporting and assist the interpretation of clinical trials comparing different PD medications. © 2010 Movement Disorder Society
Tập 25 Số 15 - Trang 2649-2653 - 2010
Clinical diagnostic criteria for dementia associated with Parkinson's disease Abstract Dementia has been increasingly more recognized to be a common feature in patients with Parkinson's disease (PD), especially in old age. Specific criteria for the clinical diagnosis of dementia associated with PD (PD‐D), however, have been lacking. A Task Force, organized by the Movement Disorder Study, was charged with the development of clinical diagnostic criteria for PD‐D. The Task Force members were assigned to sub‐committees and performed a systematic review of the literature, based on pre‐defined selection criteria, in order to identify the epidemiological, clinical, auxillary, and pathological features of PD‐D. Clinical diagnostic criteria were then developed based on these findings and group consensus. The incidence of dementia in PD is increased up to six times, point‐prevelance is close to 30%, older age and akinetic‐rigid form are associated with higher risk. PD‐D is characterized by impairment in attention, memory, executive and visuo‐spatial functions, behavioral symptoms such as affective changes, hallucinations, and apathy are frequent. There are no specific ancillary investigations for the diagnosis; the main pathological correlate is Lewy body‐type degeneration in cerebral cortex and limbic structures. Based on the characteristic features associated with this condition, clinical diagnostic criteria for probable and possible PD‐D are proposed. © 2007 Movement Disorder Society
Tập 22 Số 12 - Trang 1689-1707 - 2007
Diagnostic criteria for mild cognitive impairment in Parkinson's disease: <i>Movement</i> Disorder Society Task Force guidelines Abstract Mild cognitive impairment is common in nondemented Parkinson's disease (PD) patients and may be a harbinger of dementia. In view of its importance, the Movement Disorder Society commissioned a task force to delineate diagnostic criteria for mild cognitive impairment in PD. The proposed diagnostic criteria are based on a literature review and expert consensus. This article provides guidelines to characterize the clinical syndrome and methods for its diagnosis. The criteria will require validation, and possibly refinement, as additional research improves our understanding of the epidemiology, presentation, neurobiology, assessment, and long‐term course of this clinical syndrome. These diagnostic criteria will support future research efforts to identify at the earliest stage those PD patients at increased risk of progressive cognitive decline and dementia who may benefit from clinical interventions at a predementia stage. © 2012 Movement Disorder Society
Tập 27 Số 3 - Trang 349-356 - 2012
The Sydney multicenter study of Parkinson's disease: The inevitability of dementia at 20 years Abstract After 20 years follow‐up of newly diagnosed patients with Parkinson's disease (PD), 100 of 136 (74%) have died. The mortality rate fell in the first 3 years of treatment, then rose compared to the general population, the standardized mortality ratio from 15 to 20 years reaching 3.1. Drug induced dyskinesia and end of dose failure were experienced by most patients, but the main current problems relate to the non‐levodopa responsive features of the disease. Dementia is present in 83% of 20‐year survivors. Dementia correlates with increasing age and probably reflects an interplay of multiple pathologies. Seventeen people with dementia had postmortems. Eight had diffuse Lewy bodies as the only cause of dementia, while others had mixed neuropathology. Only one person lives independently and 48% are in nursing homes. Excessive daytime sleepiness is noted in 70%, falls have occurred in 87%, freezing in 81%, fractures in 35%, symptomatic postural hypotension in 48%, urinary incontinence in 71%, moderate dysarthria in 81%, choking in 48%, and hallucinations in 74%. The challenge is to understand the cellular mechanisms underlying the diverse features of advanced PD that go far beyond a lack of dopamine. © 2008 Movement Disorder Society
Tập 23 Số 6 - Trang 837-844 - 2008
<i>Movement</i> Disorder Society Task Force report on the Hoehn and Yahr staging scale: Status and recommendations The <i>Movement</i> Disorder Society Task Force on rating scales for Parkinson's disease Abstract The Movement Disorder Society Task Force for Rating Scales for Parkinson's disease (PD) prepared a critique of the Hoehn and Yahr scale (HY). Strengths of the HY scale include its wide utilization and acceptance. Progressively higher stages correlate with neuroimaging studies of dopaminergic loss, and high correlations exist between the HY scale and some standardized scales of motor impairment, disability, and quality of life. Weaknesses include the scale's mixing of impairment and disability and its non‐linearity. Because the HY scale is weighted heavily toward postural instability as the primary index of disease severity, it does not capture completely impairments or disability from other motor features of PD and gives no information on nonmotor problems. Direct clinimetric testing of the HY scale has been very limited, but the scale fulfills at least some criteria for reliability and validity, especially for the midranges of the scale (Stages 2–4). Although a “modified HY scale” that includes 0.5 increments has been adopted widely, no clinimetric data are available on this adaptation. The Task Force recommends that: (1) the HY scale be used in its original form for demographic presentation of patient groups; (2) when the HY scale is used for group description, medians and ranges should be reported and analysis of changes should use nonparametric methods; (3) in research settings, the HY scale is useful primarily for defining inclusion/exclusion criteria; (4) to retain simplicity, clinicians should “rate what you see” and therefore incorporate comorbidities when assigning a HY stage; and (5) because of the wide usage of the modified HY scale with 0.5 increments, this adaptation warrants clinimetric testing. Without such testing, however, the original five‐point scales should be maintained. © 2004 Movement Disorder Society
Tập 19 Số 9 - Trang 1020-1028 - 2004
Phenomenology and classification of dystonia: A consensus update ABSTRACT This report describes the consensus outcome of an international panel consisting of investigators with years of experience in this field that reviewed the definition and classification of dystonia. Agreement was obtained based on a consensus development methodology during 3 in‐person meetings and manuscript review by mail. Dystonia is defined as a movement disorder characterized by sustained or intermittent muscle contractions causing abnormal, often repetitive, movements, postures, or both. Dystonic movements are typically patterned and twisting, and may be tremulous. Dystonia is often initiated or worsened by voluntary action and associated with overflow muscle activation. Dystonia is classified along 2 axes: clinical characteristics, including age at onset, body distribution, temporal pattern and associated features (additional movement disorders or neurological features); and etiology, which includes nervous system pathology and inheritance. The clinical characteristics fall into several specific dystonia syndromes that help to guide diagnosis and treatment. We provide here a new general definition of dystonia and propose a new classification. We encourage clinicians and researchers to use these innovative definition and classification and test them in the clinical setting on a variety of patients with dystonia. © 2013 Movement Disorder Society
Tập 28 Số 7 - Trang 863-873 - 2013
The prevalence of Parkinson's disease: A systematic review and meta‐analysis Abstract Parkinson's Disease (PD) is a common neurodegenerative disorder. We sought to synthesize studies on the prevalence of PD to obtain an overall view of how the prevalence of this disease varies by age, by sex, and by geographic location. We searched MEDLINE and EMBASE for epidemiological studies of PD from 1985 to 2010. Data were analyzed by age group, geographic location, and sex. Geographic location was stratified by the following groups: 1) Asia, 2) Africa, 3) South America, and 4) Europe/North America/Australia. Meta‐regression was used to determine whether a significant difference was present between groups. Forty‐seven studies were included in the analysis. Meta‐analysis of the worldwide data showed a rising prevalence of PD with age (all per 100,000): 41 in 40 to 49 years; 107 in 50 to 59 years; 173 in 55 to 64 years; 428 in 60 to 69 years; 425 in 65 to 74 years; 1087 in 70 to 79 years; and 1903 in older than age 80. A significant difference was seen in prevalence by geographic location only for individuals 70 to 79 years old, with a prevalence of 1,601 in individuals from North America, Europe, and Australia, compared with 646 in individuals from Asia (P < 0.05). A significant difference in prevalence by sex was found only for individuals 50 to 59 years old, with a prevalence of 41 in females and 134 in males (P < 0.05). PD prevalence increases steadily with age. Some differences in prevalence by geographic location and sex can be detected. © 2014 International Parkinson and Movement Disorder Society
Tập 29 Số 13 - Trang 1583-1590 - 2014
Clinical diagnosis of progressive supranuclear palsy: The movement disorder society criteria
Tập 32 Số 6 - Trang 853-864 - 2017